Photochemotherapy (PCT) is an attractive potential cancer treatment that involves photoinduced ligand exchange of a monodentate ligand(drug) bound to a transition metal. Known Heterobimetallic complexes consisting of a ruthenium(II) polypyridyl light absorber bound through a bridging ligand to a cobalt(III) metal center have been shown to undergo ligand exchange. Visible light absorption by the ruthenium center results in electron transfer, effectively reducing the cobalt center to cobalt(II) . While the cobalt(III) center is inert, the ligands on the cobalt(II) center become labile, leading to photoexchange. Discussed herein is the synthesis and characterization of a Ru(II),Co(III) bimetallic complex [(bpy)2Ru(bpm)Co(tpy)L](PF6)5 (bpy = 2,2ʹ-bipyridine; bpm = 2,2ʹ-bipyrimidine; tpy = 2,2ʹ:2ʺ,6ʹ-terpyridine, L = pyridyl-, amine- or nitrile-containing drug). Photochemical, photophysical, and electrochemical studies are done to investigate the complex as a potential PCT agent.

Light-activated drug release using heterobimetallic ruthenium and cobalt complexes

249th National Meeting (2015)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.